One sentence summary: Immunized mice with CpG-ODNs, and Chitosan-adjuvanted Tat vaccines elicited stronger T-cell responses (both humoral and cellular immunity) compared to mice immunized with Alum-adjuvanted Tat and recombinant Tat protein alone. Editor: Alfredo Garzino-Demo ABSTRACT HIV1-Tat-based vaccines could elicit broad, durable and neutralizing immune responses and are considered as potential AIDS vaccines. The present study aims to formulate CpG-ODNs adjuvant and Chitosan with Tat protein to enhance the immunogenicity of HIV-1-Tat-based candidate vaccines and to investigate their efficacies in mice. To this end, we added CpG-ODNs, Chitosan and Alum as adjuvants to the Tat-based candidate vaccine formulations. Then, we compared frequency and magnitude of both humoral and cellular immune responses from mice immunized with the adjuvant-formulated Tat candidate vaccines against those obtained from mice immunized with recombinant Tat protein alone. Mice were subcutaneously immunized three times at 2-week intervals with the candidate vaccines. Measurements of anti-Tat immune responses showed that all vaccinated groups had a good immunity compared to the control groups and developed high levels of both humoral and cellular responses. However, immunized mice with CpG-ODNs, and Chitosan-adjuvanted Tat vaccines elicited stronger T-cell responses (both humoral and cellular immunity) compared to the others. These data suggest that co-administration of recombinant Tat protein with CpG-ODNs and Chitosan may serve as a potential formulation for enhancing of the Tat vaccine-induced immunity and might have effects on shaping Th polarization induced by HIV1-Tat protein vaccines.
INTRODUCTION
Since HIV (human immunodeficiency virus) was identified as the causative agent of AIDS (acquired Immunodeficiency Syndrome; Gallo et al. 1984; Montagnier et al. 1984) , various candidate HIV-1 vaccines have been developed (Spearman 2003; Girard and Plotkin 2012) . However, vaccines against HIV/AIDS are not still available due to the tremendous genetic diversity of HIV-1 strains (Spearman 2003) . Indeed, an efficacious global HIV-1 vaccine should be able to elicit potent, durable and comprehensive immune responses for providing protection against highly diverse HIV-1 variants (Cafaro et al. 2001; Ensoli et al. 2009 ).
The multifunctional early expressed protein Tat (transactivator of transcription) is one of the most important proteins of HIV-1 playing critical roles in the virus transcription, pathogenesis and the promotion of cellular survival (Romani, Engelbrecht and Glashoff 2010; Johri et al. 2011) . It has been also shown that HIV-1 Tat protein is effectively involved in AIDS-associated tumors (Barillari and Ensoli 2002; Nunnari, Smith and Daniel 2008) and HIV-associated neuropathogenesis (King et al. 2006) . The protein is encoded by two exons and includes five functional domains. There is a relatively high degree of tat gene sequence conservation among the HIV-1 clades (Pugliese et al. 2005; Johri et al. 2011) . This viral protein is a small nuclear transcriptional activator protein containing 86-104 amino acid residues and has visible molecular weight of 14-16 kDa in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Brake et al. 1990; Caputo et al. 2009 ). In HIV infection, acutely infected CD4+ T lymphocytes release relatively high levels of Tat protein that it is detectable in the sera of the HIV-infected individuals. After that, it is uptaken by heparan sulfate proteoglycans of dendritic cells (DC) and then processed by monocyte-derived DC. After processing pathway and eliciting immune responses of the Th1-type profile, T-cell responses finally increase (Rusnati and Presta 2002; Caputo et al. 2009; Shao 2014) . Regards to the crucial roles of Tat protein, it is considered as a very suitable and important target for HIV-1 vaccines. Previous studies revealed that vaccines based on the native HIV-1 Tat protein have been immunogenic, safe, well tolerated and effective in preclinical models and could be used as both 'preventive' and 'therapeutic' vaccines. Meanwhile, it was shown that Tat protein also simultaneously possesses immunomodulant and adjuvant properties. According to the previous results, Tat-based vaccines enhanced the cytotoxic T-lymphocyte (CTL) responses, the anti-Tat antibody titers and the Th1-type immune responses (Dale et al. 2004; Ensoli et al. 2009; Fraternale et al. 2011) . The results also showed that the HIV-1 Tat protein has protective effects in control of the disease progression ).
On the other hand, according to the several studies, the addition of various potent adjuvants to the administered antigen can also induce stronger immune responses against the desired antigen (Cui et al. 2004) . Moreover, because of adjuvants safety, simplicity, efficacy and capacity for repeated administration, the interest in their applications has been increasingly enhanced in the recent years (Mohan, Verma and Rao 2013) . Oligodeoxynucleotides (ODNs) with unmethylated CpG dinucleotides mimic the immune stimulatory activity of bacterial DNA in vertebrates (Vollmer et al. 2004) . Toll-like receptor 9 (TLR9) recognizes CpG motif and then signaling is initiated. The signaling pathway proceeds through the stimulation of MyD88, IRAK and TRAF-6. TLR9-mediated activation eventually elicits the innate (characterized by the production of proinflammatory cytokines, chemokines, type I interferons and antimicrobial peptides) and adaptive immune responses (characterized by the expansion of antigen (Ag)-specific T and B cells; Roberts et al. 2005; Kumagai, Takeuchi and Akira 2008) . To date, four classes of synthetic CpGODNs have been described which possess distinct structural and biological properties (Samulowitz et al. 2010) . CpG-ODNs have already been used as adjuvant to induce innate and adaptive immune responses for cancer treatment (Stern, Boehm and TaryLehmann 2002) . There is also a report on the application of CpG-ODNs with the 11-mer HIV-derived peptide Tat (47-57) to form structures inducing of antiviral and anticancer type I interferon production (Samulowitz et al. 2010) . Moreover, Becker (2005) has reviewed intranasal and intradermal administrations of vaccines containing CpG-ODNs combined with synthetic HIV-1 peptides to treat HIV-1/AIDS patients (Becker 2005) .
On the other hand, given that the Tat protein is unstable and digested by the proteases, the addition of Chitosan to the administered Tat antigen can protect it from protease digestion and also increase the uptake of Tat protein by the immune cells.
Chitosan has also already received Food and Drug Administration approval for dietary regimen (Zou et al. 2016) . According to the literature, this compound has been used for delivery of HIV-1 Tat-based vaccines (Grdiša and Mikecin 2008) , but its efficacy and immune adjuvant properties in these candidate vaccines have not been published yet. Moreover, there is no still comparative study that evaluates Chitosan immunogenic potency in comparison with the other available human compatible adjuvants. To designate the immune adjuvant properties of CpGODNs and Chitosan (human-compatible adjuvants) to enhance the immunogenicity of HIV-1 Tat protein-based vaccines and to investigate their efficacies in mice model, in the present study after expression, purification and preparation of the recombinant Tat protein, the frequency and magnitude of both humoral and cellular immune responses from BALB/c mice immunized with either CpG-ODNs and Chitosan-adjuvanted Tat were measured for the first time and compared to those from mice immunized with the Alum-adjuvanted Tat and also recombinant Tat protein alone.
MATERIALS AND METHODS

Chemicals
Adjuvants CpG-ODNs, Chitosan and Alum, horseradish peroxidase (HRP)-conjugated antimouse IgG and goat antimouse IgG 1 and IgG 2a secondary antibodies were purchased from Sigma (St. Louis, MO, USA). The pET28a-HIV1-tat vector was from Pasteur Institute of Iran (Tehran, Iran). Kanamycin and isopropyl-D-thiogalactopyranoside (IPTG) were obtained from Invitrogen (Carlsbad, CA, USA). The Ni-NTA agarose was provided by Qiagen (Hilden, Germany). Roswell Park Memorial Institute medium (RPMI) 1640 was obtained from (Gibco, Germany). Lactate dehydrogenase (LDH) assay kit and BrdU kit were purchased from Takara (Tokyo, Japan), and all the other chemicals were obtained from Merck (Darmstadt, Germany). Reproducibility of the data presented in this paper was confirmed by repeating the experiments at least three times. The data presented here are typical experimental data.
Expression and purification of the recombinant Tat protein
The pET28a (+) containing HIV1-tat gene was first transformed into the competent cells Escherichia coli DH5α, in order to increase the copy number of plasmid, and then transformed to E. coli BL21 (DE3) by a chemical method (Sambrook and Russell 2001) . For protein production, the transformed E. coli BL21 (DE3) host cells were cultivated in 5 ml of Luria-Bertani broth (LB) medium with kanamycin (50 μg ml −1 ) at 37
• C with reciprocal shaking (250 rpm) for 12-14 h. Precultured cells were then used to inoculate production medium at a concentration of 1% (v/v) and added to 250 ml of LB medium in 1 l Erlenmeyer flasks and induced with 1 mM IPTG when the culture reached an OD 600 of 0.5-0.7. After addition of IPTG, the cultivation was continued for 4 h at 37
• C with reciprocal shaking (250 rpm). The medium was finally cooled down, and the cells were harvested from cultures by centrifugation at 5000 rpm for 20 min. The supernatant was discarded and the pellet was stored at -20 • C overnight. For protein purification, bacterial pellets were re-suspended in lysis buffer containing 50 mM Tris-base, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM PMSF and 10% (v/v) glycerol and disrupted with ultrasound at 0 • C. The cellular fractions were cleared by centrifugation at 12 000 rpm for 20 min at 4 • C. Since the recombinant Tat protein included a His 6 -tag at its N-terminus, purification of the protein was carried out using a Ni-NTA agarose column and the resultant supernatants were applied on the column equilibrated with 50 mM NaH 2 PO 4 (pH 8.0), 600 mM NaCl and 50 mM imidazole (buffer A). The column was washed as step gradients with the required volume of the same buffer containing 2% Triton X-100 and increasing concentrations of imidazole (50, 100 and 150 mM) in different washing steps. Finally, the adsorbed proteins were eluted with the required volume of 50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl and 250 mM imidazole (buffer B). The purity of the protein was confirmed by 15% SDS-PAGE analysis (Laemmli 1970 ) and total protein concentrations were estimated by the Bradford method (Bradford 1976) using Coomassie blue with bovine serum albumin (BSA) as the standard protein. After SDS-PAGE verification, the collected pure fractions were dialyzed against 50 mM phosphate saline buffer (PBS) (pH 7.2) by gentle stirring at 4
• C for overnight and finally stored at -20
• C till used. The endotoxin content of different fractions was measured by Limulus amoebocyte lysate (LAL, Lonza, Switzerland) according to the manufacturer's instructions.
Immunization of mice
Six to eight-week-old inbred female mice (BALB/c) from Pasteur Institute of Iran (Tehran, Iran) were used for all animal studies. National Institutes of Health (NIH) guidelines for the care and use of laboratory animals were observed. The mice were randomly divided into eight groups with six mice per group and were immunized three times at 2-week intervals with candidate vaccines (Table 1 ). Mice were immunized by subcutaneous injection on days 0, 14 and 28 with either Tat alone, Tat adjuvanted with Alum, Tat adjuvanted with CpG-ODNs and Tat adjuvanted with Chitosan. Control mice were subcutaneously immunized with the adjuvant alone and sterile PBS.
Lymphocyte proliferation assay
Fourteen days after the third and final immunization, spleens from each group of mice were removed and placed into sterile Petri dishes containing 5 ml of RPMI 1640. After homogenization and centrifugation (2000 rpm, 15 min, 4
• C), the cell pellets were re-suspended in 2.5 ml lysis buffer (containing 90 ml of 0.16 M NH 4 Cl and 10 ml of 0.17 M Tris, pH 7.2) and incubated for 5 min on ice for RBCs lysis. After centrifuging (2000 rpm, 15 min, 4
and pouring off the supernatant, the cell pellets were washed twice with RPMI medium and re-suspended in 1 ml RPMI 1640 supplemented with 10% Fetal bovine serum (FBS), 1 mM sodium pyruvate, 4 mM L-glutamine, 100 μg/ml streptomycin and 100 IU/ml penicillin. For lymphocyte proliferation assay, 100 μl of isolated splenocytes with three replicates were seeded into a 96-well plate and stimulated with 10 μg/well of the recombinant Tat protein as antigen recall and the 5μg/ml of Concanavalin A (Con A) as positive control. Unstimulated wells were used as negative controls and complete culture medium was used as blank. After incubation at 37
• C with 5% CO 2 for 72 h, 20 μl of BrdU (5-bromo-2 -deoxyuridine) labeling solution was pipetted into each well. After an additional of 18 h incubation at 37
• C with 5% CO 2 , the culture medium was removed by centrifugation and 100 μl of anti-BrdU antibody was added to each well. The plates were washed three times with wash buffer (PBS, pH 7.2), then the tetramethylbenzidine substrate solution was added and finally the reaction was stopped by adding 100 μl of 2N H 2 SO 4 . The optical density (OD) for each well at 490 nm was measured using a Universal Microplate Reader (Biohit 8000, USA). The cell proliferation was reported as the stimulation index (SI). The formula of SI was OD of stimulated wells/OD of un-stimulated wells.
Measurement of IFN-γ production
The enzyme-linked immunosorbent assay (ELISA) assay was carried out using a commercial kit from R&D Systems (Duo Set, USA). Briefly, the cytokine capture antibody against mouse IFN-γ was dispensed into a 96-well micro plate with 100 μl per well by overnight incubation at 4
• C. After washing with wash buffer (0.05% Tween 20, PBS, pH 7.2), the plates were blocked with blocking buffer containing 0.1% BSA in PBS, for 2 h at room temperature. Then, 100 μl of prepared mice splenocytes (a number of 4 × 10 6 cells/well) was added into the 24-well plate, stimulated in vitro with 10 μg/ml of recombinant Tat protein as antigen recall and incubated at 37
• C in 5% CO 2 for 72 h. The supernatants were collected by centrifugation (300 g for 10 min) and 100 μl of supernatant was added into each well. After that the plates were incubated at room temperature for 2 h and washed four times. One hundred microliter of biotinylated detection antibody against mouse IFN-γ was added into each well and incubated for 2 h. After washing, 100 μl of the freshly prepared Streptavidin-HRP was added into each well, and the plates were incubated for 20 min and then were washed five times and incubated with 100 μl of 3,3 ,5,5 -Tetramethylbenzidine (TMB) substrate in dark place for 30 min. Finally, 50 μl of stop solution (2 N H 2 SO 4 ) was added. The OD was determined at 450 nm using a Multiscan enzymelinked immunosorbent assay plate reader (Biohit 8000, USA). 
Analysis of anti-Tat antibody levels by ELISA
CTL assay
For evaluation of cellular immune responses, the recovered and washed CTLs were employed as effector cells in an LDH release assay (Roohvand et al. 2007) . For preparation of the effector cells, 14 days after the final immunization, a number of 2 × 10 6 cells/ml single-cell splenocytes were cultured, stimulated with 10 μg/ml Tat protein, certain amounts of Tat and desired adjuvants and incubated for 72 h at 5% CO 2 , 37
• C. SP2/0 tumor cells were used as target cells in the present study. These cells have been derived from the syngeneic BALB/c mouse myeloma and are used as target cells for CTL assays (Tao et al. 2011) . The effector cells were co-cultured with epitope-pulsed SP2/0 target cells at the effector/target ratios of 100:1 and incubated for 5 h at 5% CO 2 , 37
• C. Since MHC-1 recognizes linear epitopes (Abbas, Lichtman and Pillai 2014), we used linear epitope of GRKKRRQRRRAHQN) ). Lysis of target cells was quantified using the LDH assay kit (Takara) according to the manufacturer's instruction. The LDH-mediated conversion of the tetrazolium salt into red formazan product was measured at 490 nm after incubation at room temperature for 30 min. The lysis percentage was calculated by the formula:
Specific cytolysis (%) = [(experimental lysis -spontaneous effector lysis -spontaneous target lysis)/ (target maximum lysis -target spontaneous lysis)] × 100.
Controls include PBS as blank and a solution of 0.1% Triton X-100 in PBS as maximum LDH release of target cells (Memarnejadian and Roohvand 2010).
Th1:Th2 index calculation
After measurement of IgG 1 and IgG 2a , the Th1:Th2 indexes were calculated according to the formula of IgG 2a /IgG 1 . A value of the index above 1 shows a shift of the immune response toward the Th1 type (cellular immunity), whereas the value of the index below 1 means a shift of the immune response toward the Th2 type (humoral immunity) (Liu et al. 2013) .
Statistical analyses
All experiments were considered in triplicates and/or repeated three times, and the data were compared as means ± SD of each experiment. Prism 6.01 software (GraphPad Software Inc., San Diego, CA, USA) was used for the data handling, and the statistical analyses were performed using one-way ANOVA followed by Turkey's HSD test. In all of the cases, P-values < 0.05 were considered to be statistically significant.
RESULTS
Expression and purification of the recombinant HIV-1 Tat protein
For preparation of HIV-1 Tat-based vaccines, the His 6 -tagged Tat protein expressed from pET28a in the Escherichia coli BL21 (DE3) was efficiently purified by affinity chromatography using a Ni-NTA agarose column. In order to remove the LPS endotoxin from the recombinant Tat protein expressed in E. coli, Triton X-100 was used at 2% concentration to extensively wash the column as Tat was immobilized on the column. According to the literature, in this concentration of the detergent, endotoxins are efficiently separated from the aqueous phase (Siddappa et al. 2006) . To confirm this, we also measured the endotoxin content of different fractions. The results revealed that the final concentration of endotoxin in the eluted Tat solutions was 0.05 EU/ml. The eluted protein fractions were then collected for SDS-PAGE anal- ysis. On SDS-PAGE under heat-denatured conditions, the purified Tat protein showed a purity of 95% and migrated to around 16 kDa (Fig. 1) , as reported for the protein (Johri et al. 2011) . Finally, the dialysis of the collected fractions and determination of the protein concentrations were carried out as described in materials and methods.
Lymphocyte proliferation assay
For lymphocyte proliferation assays, BALB/c mice were subcutaneously immunized with Tat, Tat adjuvanted with Alum, Tat adjuvanted with CpG-ODNs and Tat adjuvanted with Chitosan on days 0, 14 and 28. Finally, the cellular immune responses induced by vaccination were evaluated by BrdU method and the SI values were calculated (Fig. 2) . The results showed that lymphocytes proliferative responses increased significantly in the vaccinated groups compared to the control groups (P < 0.05). Whereas the groups immunized with Tat+CpG-ODNs adjuvant and Tat+Chitosan displayed the highest SIs compared to the other groups, there is no significant difference between them (P > 0.05). It seems that the vaccination with the Tat protein formulated with CpG-ODNs and Chitosan adjuvants has dramatically induced specific cellular immune responses in vaccinated mice. 
Determination of antibody levels
To determine whether the candidate vaccines can elicit Tatspecific antibodies IgG 1 and IgG 2a , mice were subcutaneously immunized with HIV-1 Tat protein alone, Tat+CpG-ODNs, Tat+Alum and Tat+Chitosan on days 0, 14 and 28. One week after the last injection, the stimulation of humoral immune responses was evaluated. The results revealed that immunization of mice with the recombinant Tat protein alone and formulated with desired adjuvants resulted in significant increases in both IgG 1 and IgG 2a antibody titers in the sera of vaccinated mice against the control groups ( Fig. 3A and B, respectively) . Moreover, while antibody levels are higher in mice immunized with adjuvant-formulated candidate vaccines (Tat+Alum, Tat+CpG-ODNs and Tat+Chitosan) compared to those immunized with Tat protein alone (P < 0.05), no significant differences were detected among these three groups.
Cellular immunity
To evaluate the cellular immune responses induced by vaccination, the presence of Tat-specific IFN-γ secreting cells was measured by ELISA method. As shown in Fig. 4 , enhanced cellular immune responses to the HIV1-Tat antigen were observed in the groups vaccinated with HIV-1 Tat protein alone and Tat adjuvanted with CpG-ODNs, Alum and Chitosan compared to the control groups. Moreover, the results revealed while mice immunized with Tat adjuvanted with CpG-ODNs, Alum and Chitosan showed significantly higher levels of IFN-γ than those immunized with Tat protein alone, there was no statistically significant difference among these three groups.
CTL responses
The Tat-specific CTL activities were measured by LDH-releasing method. Two weeks after last immunization, the splenocytes from immunized mice were re-stimulated in vitro with Tat protein for 72 h and then co-cultured with target cells SP2/0 for 5 h. As seen in Fig. 5 , the CTL responses were significantly higher in groups vaccinated with HIV-1 Tat protein alone and Tat adjuvanted with CpG-ODNs, Alum and Chitosan compared to the control groups (P < 0.05). Also, the candidate vaccines containing Tat adjuvanted with CpG-ODNs and Tat adjuvanted with Chitosan led to the highest responses, respectively. 
The effects of candidate vaccines on the Th polarization
The IgG 1 (Th2 polarization) and IgG 2a (Th1 polarization) subclass responses generated by candidate vaccines were assessed by calculating the Th1:Th2 index according to the formula of "IgG 2a /IgG 1 " (Liu et al. 2013) . The results showed that the Th1:Th2 
DISCUSSION
The main targets of novel HIV vaccines are blocking of the virus replication (by including HIV important regulatory genes, such as Tat) and the simultaneous induction of broad humoral and cellular immune response (Ensoli et al. 2006; Titti et al. 2007) . As reported in the previous studies, the early expressed regulatory HIV-1 Tat protein is indispensable for the virus replication and pathogenesis and since possesses intrinsic adjuvant properties; it can also provide adjuvanticity for other antigens. The unique properties of this viral protein including its early expression, high degree of conservation and immunogenicity, have suggested the effective application of the protein for vaccine development studies, both in preventive and therapeutic perspectives (Caputo et al. 2009; Johri et al. 2011; Rahma et al. 2014; Shao 2014) . Several studies have especially determined the blocking HIV replication by targeting Tat protein, and different classes of new compounds have also been discovered that act by inhibiting Tat, and so, interfere with HIV-1 replication. As previously suggested, a Tat vaccine, based on the biologically active Tat protein alone, may reduce HIV-1 replication and so help to reduce disease progression in seropositive individuals. Moreover, Mhashilkarl et al. showed that intrabodies against Tat protein can inhibit virus replication (Chen et al. 1994; Caputo et al. 2009; Hamy et al. 2000; Mhashilkar et al. 1995) . According to the previous results, lower rate of incidence and lower risk of progression to advanced HIV disease is seen among individuals with antibodies against Tat compared to anti-Tat negative individuals (Ensoli et al. 2005 (Ensoli et al. 2009 ).
On the other hand, enhanced humoral (Patel et al. 2006) and cellular immune responses (Cui et al. 2004; Castaldello et al. 2006) were also observed in mice vaccinated with the HIV-1 Tat protein formulated with adjuvant components. According to these studies, HIV-1 Tat-based vaccines formulated with Alum adjuvant induced strong humoral immune responses (Cui et al. 2004) .
In the present study, the simultaneous induction of both humoral and cellular immune responses in mice immunized subcutaneously with the HIV-1 Tat candidate vaccines adjuvanted with CpG-ODNs and Chitosan was investigated and the results were compared with those obtained from mice vaccinated with Tat protein alone and Tat adjuvanted with Alum. It is well known that the route of vaccine administration is important to determine its efficiency/efficacy, and subcutaneous injection can stimulate both humoral and cellular immune responses at the same time (Cazeaux et al. 2002) .
The cellular immune responses are very important in controlling of viral infections, and an effective vaccine against HIV will need to elicit both cellular and humoral immune responses. It was previously reported that HIV-1 Tat-based vaccines could induce lymphocyte proliferation (Cui et al. 2004) . The results obtained from the lymphocyte proliferation assays (as an indicator of cellular immunity) (Fig. 2) showed that all candidate vaccines (Tat protein alone, Tat+CpG-ODNs, Tat+Alum and Tat+Chitosan) induced T-cell proliferative responses efficiently. The adjuvants CpG-ODNs and Chitosan elicited higher proliferative responses than the HIV-1 Tat protein alone or Tat adjuvanted with Alum. These results are consistent with our predictions on the basis of previous literature (Caputo et al. 2009 ). According to these studies, CpG-based adjuvants can affect the cellular immune responses and activate both innate and adaptive immune responses by inducing of plasmacytoid DC and B cells. CpG-ODNs can also significantly enhance the number and survival of CD8 + T cells (Ballas, Rasmussen and Krieg 1996; Klinman et al. 1996) . On the other hand, it has been shown that Chitosanbased vaccines widely stimulate both humoral and cellular immune responses (Jabbal-Gill, Watts and Smith 2012). Titration of sera antibodies in the current study revealed the parallel secretion of IgG 1 (as the indicator of Th2 and humoral response) and IgG 2a (as the indicator of Th1 and cellular response) (Liu et al. 2013) confirming the active induction of both immune system arms ( Fig. 3A and B for IgG 1 and IgG 2a , respectively). According to these results, all of the Tat-based vaccines (with or without adjuvant) were significantly able to induce specific antibody responses. Mice immunized with adjuvantformulated Tat vaccines showed higher antibody titers compared to the group immunized with Tat protein alone. Humoral responses are highly important in prevention of viral infections and neutralizing viruses (Mascarell et al. 2005) . Several studies have shown that the Tat-based vaccines can increase humoral immune responses against HIV-1 and be sufficient to generate strong specific anti-Tat humoral responses that exhibit potent Tat-neutralizing capacities (Caputo et al. 2009) .
As cytokines play an important role in T-cell polarization (Alhetheel, Aly and Kryworuchko 2013) , measurement of IFN-γ production in the supernatant from spleen cells activated in vitro could be informative. The IFN-γ expressed from T cells was relatively higher in mice vaccinated with Tat adjuvanted with CpG-ODNs, Alum and Chitosan compared to the group vaccinated with Tat protein alone, indicating a Th1-type and cellular immune responses in these groups (Fig. 4) . It is well known that HIV-1-specific CD4 + T cells play a key role in controlling of HIV-1 early infection and the increased levels of IFN-γ might contribute to decrease of the release of HIV-1 virions (Parham 2014) . It was already reported that HIV-1 Tat-based vaccines (both DNA and protein) can induce the production of increased levels of the IFN-γ that it is important in controlling viral infection (Partidos et al. 2004; Rolland et al. 2007) . High levels of IFN-γ can limit viral set point and improve the course of HIV-1 disease (Abbas, Murphy and Sher 1996) . On the other hand, it is said that an ideal vaccine would be one that induces strong CTL responses (Girard et al. 2011) . It has been reported that adjuvant-formulated Tat DNA vaccines can induce effective CTL responses against HIV infection in vaccinated mice (Bozac et al. 2006) , but CTL responses have not been studied much. The results of the current investigation indicate that HIV-1 Tat-based candidate vaccines formulated with CpG-ODNs and Chitosan adjuvants can induce effective CTL responses in vaccinated mice, compared to the Tat protein alone and Tat+Alum candidate vaccines (Fig. 5) . Considering the critical roles of cellular immune responses in the fight against HIV infection, induction of strong CTL responses by HIV-1 Tat-based vaccines formulated with CpG-ODNs and Chitosan adjuvants could be considered as one of the noticeable advantages of these candidate vaccines.
In the current study, the Th-polarization responses in mice were determined according to the value of IgG 2a /IgG 1 (Table 2) . The results revealed that the Tat-based candidate vaccines formulated with CpG-ODNs and Chitosan adjuvants shifted the responses toward the Th1 immunity (cellular immunity). Meanwhile, these results suggest that the Th1-polarization responses induced upon the addition of CpG-ODNs or Chitosan to the Tatbased vaccines' formulation could turn the Th2-polarization responses induced by Tat alone or Tat adjuvanted with Alum to the more balanced Th1/Th2 immune responses in mice. These results are consistent with the results from other groups (Ensoli et al. 2008) . They found that in HIV-infected asymptomatic individuals vaccinated intradermally with Tat alone, not only functional antibodies are induced, but also the marked Th1 polarization of anti-Tat immunity seen in natural infection is partially reverted. However, it is important to notice that according to some literature, the pattern of Th1/Th2 (or IgG 2a /IgG 1 ) responses induced by the recombinant Tat protein were different between cynomolgus macaques and mice (Turbant et al. 2009 ) and so, it might be different between human and mice, too.
CONCLUSION
Although the promising results have so far been obtained with the HIV-1 Tat-based vaccines in animals and humans, there still exists a great emphasis on the development of vaccines be simultaneously able to induce strong cellular and humoral immune responses. In this respect, development of new safe adjuvants, assessment of different formulations of available human compatible adjuvants, evaluation of the effects of various routes of vaccine administration on its efficiency/efficacy and parallel comparison of the effects of different adjuvants on elicitation of humoral and cellular responses are completely critical and provide valuable assessments of vaccines' effectiveness.
Taken together, we evaluated the adjuvant effects of CpGODNs and Chitosan in vaccines based on HIV-1 Tat protein and compared them with those obtained from Alum-adjuvanted Tat and Tat protein alone vaccines. Totally, the results showed that although all vaccinated groups had a good immunity compared to the control groups, mice vaccinated with Tat+CpG-ODNs and Tat+Chitosan developed high levels of humoral and cellular responses simultaneously. These data suggest that CpGODNs and Chitosan adjuvants can be potent adjuvants and co-administration of the recombinant Tat protein with CpGODNs and/or Chitosan may serve as a potential formulation for enhancing of the Tat vaccine-induced immunity. Moreover, it seems that CpG-ODNs and or Chitosan-adjuvanted Tat vaccines might have effects on shaping Th polarization induced by HIV-1-Tat protein vaccines. Our results, in agreement with other studies, suggest that biologically active Tat protein-based vaccines are among efficient candidate vaccines against HIV-1 and when formulated with CpG-ODNs and/or Chitosan adjuvants can induce stronger Tat-specific humoral and cellular immune responses and could be further developed into a novel vaccine component to optimize HIV vaccines in clinical trials. Although these candidate vaccines still need more optimizations in respect of their safety, immunogenicity and efficacy profiles, however, our findings indicate the potency of HIV-1 Tat-based vaccines formulated with CpG-ODNs and or Chitosan adjuvants as a promising strategy for the improvement of HIV-1 vaccines.
